Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1805 results
August 2020
-
Media ReleaseNovartis receives EC approval for new Xolair® indication to treat severe chronic rhinosinusitis with nasal polypsEC approves Xolair® (omalizumab) as an add-on therapy for severe chronic rhinosinusitis with nasal polyps, the first anti-immunoglobulin E antibody approved in this indication1 Chronic…
-
Media ReleaseNovartis announces NEJM publication of Phase III ASCLEPIOS trials demonstrating superior efficacy of ofatumumab in patients with relapsing multiple sclerosisOfatumumab is a targeted B-cell therapy that delivers superior efficacy with a similar safety profile when compared with teriflunomide, a commonly prescribed oral treatment for multiple sclerosis1…
-
Media ReleaseNovartis announces Kymriah® meets primary endpoint at interim analysis of pivotal study in follicular lymphomaGlobal ELARA trial demonstrated clinically meaningful benefit in patients with relapsed or refractory (r/r) follicular lymphoma (FL) as measured by complete response rate Kymriah previously…
-
Media ReleaseNovartis Cosentyx® receives EU approval for first-line systemic treatment in pediatric psoriasisEU approval is based on two Phase III studies showing Cosentyx® provides fast and strong skin clearance, along with significant improvement in quality of life and a favorable safety profile1 …
July 2020
-
Collaborating to explore new gene regulation therapies
Novartis and Sangamo Therapeutics plan to pursue potential treatments for neurodevelopmental diseases.
-
Media ReleaseNovartis receives Piqray® approval in Europe – the first and only targeted medicine for HR+/HER2- advanced breast cancer with a PIK3CA mutationPiqray (alpelisib) is the only treatment approved specifically to address PIK3CA mutation, underscoring Novartis commitment to reimagining cancer care Approval based on SOLAR-1 Phase III trial…
-
StatementChoice with Responsibility: Reimagining how we work
-
Media ReleaseSandoz announces plans for joint investment to help strengthen future of antibiotics manufacturing in EuropeSandoz and Austrian government announce joint plans to drive long-term competitiveness of European production for key antibiotics in Europe Planned combined investment of more than EUR 150…
-
Media ReleaseNew Novartis analysis shows wet AMD patients achieved sustained fluid control faster with Beovu® versus afliberceptA post-hoc analysis of the HAWK and HARRIER trials presented at ASRS showed >=50% of patients achieved sustained retinal dryness by weeks 8 and 4 with Beovu and by weeks 12 and 8 with aflibercept…
-
Breaking a vicious cycle of inflammation
Novartis researchers aim to quash inflammation to treat chronic disease.
-
Media ReleaseNovartis Adakveo® receives positive CHMP opinion for the prevention of recurrent vaso-occlusive crises in patients with sickle cell diseaseIf approved, Adakveo would be the first targeted sickle cell disease therapy available for use in Europe CHMP opinion supported by data showing Adakveo significantly reduced the rate of vaso-…
-
Featured NewsExpanding CAR-T manufacturing in Europe to serve more patients
European Medicines Agency (EMA) recently approved two European Novartis sites for commercial CAR-T manufacturing.
Pagination
- ‹ Previous page
- 1
- …
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- …
- 151
- › Next page